Home Tags MCRPC

Tag: mCRPC

Phase 1/2 Clinical Trial Evaluates PDS0301 + Docetaxel in Patients Diagnosed...

A first study designed evaluate docetaxel, the current standard-of-care chemotherapy (SOC), in combination with PDS0301*, a novel antibody-drug conjugate or ADC, in patients diagnosed with metastatic castration sensitive (mCSPC) and castration resistant (mCRPC) prostate cancer, has shown a decrease in prostate specific antigen (PSA) levels in all patients participating in the clinical study.

FDA Grants Fast Track Designation for ARX517 in Metastatic Castration-Resistant Prostate...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARX517, a proprietary anti-PSMA antibody-drug conjugate (ADC) investigational being therapy developed by Ambrx for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.